17 completed. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 17 |
| Phase 2 | 1 | Completed 1 |
Follow Abdominal Neoplasms: new trials by email Literature Review of Abdominal Neoplasms trials Research Report on Abdominal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Pembrolizumab, Placebo for pembrolizumab, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1367 | 2018-12-18 | 2026-08-19 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel, Carboplatin, Atezolizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Hoffmann-La Roche | 1301 | 2017-03-08 | 2023-02-17 |
| Adjuvant HIPEC in High Risk Colon Cancer Adjuvant HIPEC (open/laparoscopic), Standard adjuvant systemic chemotherapy, Diagnostic laparoscopy - Colorectal Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 204 | 2015-03-01 | 2021-09-16 |
| Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis HIPEC - Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum | Phase 3 | Completed | Charite University, Berlin, Germany | 105 | 2014-03-01 | 2021-07-29 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trabectedin, DOXIL, Dexamethasone - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Janssen Research & Development, LLC | 581 | 2013-10-16 | 2019-04-01 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Bevacizumab, Paclitaxel, Carboplatin - Genital Diseases, Female, Ovarian Diseases | Phase 3 | Completed | AGO Study Group | 927 | 2011-11-01 | 2022-07-20 |
| Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients laparotomy plus HIPEC - Colorectal Cancer With a Resected Minimal Synchronous PC, Ovarian Metastases | Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 150 | 2010-06-11 | 2026-04-06 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Placebo, Paclitaxel, BIBF 1120 - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Boehringer Ingelheim | 1366 | 2009-11-17 | 2017-12-07 |
| Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer perioperative fluid management, perioperative fluid treatment - Surgery, Perioperative Care | Phase 3 | Completed | Nanjing PLA General Hospital | 179 | 2009-05-01 | 2011-07-22 |
| Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer fluorouracil, leucovorin calcium, oxaliplatin - Colorectal Cancer, Primary Peritoneal Cavity Cancer | Phase 3 | Completed | UNICANCER | 264 | 2008-02-01 | 2016-08-30 |
| Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery enoxaparin, Physical prophylaxis - Abdominal Neoplasms | Phase 3 | Completed | Sanofi | 151 | 2007-03-01 | 2010-04-05 |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer phenoxodiol, carboplatin, placebo - Fallopian Tube Cancer, Peritoneal Neoplasms | Phase 3 | Completed | MEI Pharma, Inc. | 142 | 2006-10-01 | 2016-07-18 |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas MiCK Assay - Adenocarcinoma, Ovarian Neoplasms | Phase 2 / Phase 3 | Completed | Pierian Biosciences | 150 | 2006-03-01 | 2018-03-12 |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer EPO906 (Patupilone), doxorubicin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 829 | 2005-11-01 | 2020-12-17 |
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Lanreotide (microparticle formulation), Placebo - Intestinal Obstruction, Carcinoma | Phase 3 | Completed | Ipsen | 80 | 2003-09-01 | 2020-11-05 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Gemcitabine, Paclitaxel, Carboplatin - Genital Neoplasms, Female, Fallopian Tube Neoplasms | Phase 3 | Completed | Eli Lilly and Company | 919 | 2002-10-01 | 2011-03-04 |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Gemcitabine, liposomal doxorubicin - Genital Neoplasms, Female, Fallopian Tube Neoplasms | Phase 3 | Completed | Eli Lilly and Company | 162 | 2002-07-01 | 2007-01-26 |
Peritoneal Neoplasms (15) · Ovarian Neoplasms (10) · Fallopian Tube Neoplasms (9) · Carcinoma, Ovarian Epithelial (2) · Colorectal Neoplasms (2) · Genital Neoplasms, Female (2) · Pelvic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Colonic Neoplasms (1) · Genital Diseases, Female (1) · Intestinal Obstruction (1) · Krukenberg Tumor (1) · Neoplasms (1)
Neoplasms by Site (17) · Neoplasms (16) · Digestive System Diseases (15) · Digestive System Neoplasms (15) · Peritoneal Diseases (15) · Adnexal Diseases (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Gonadal Disorders (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10)
Carboplatin (6) · Paclitaxel (5) · Bevacizumab (3) · Gemcitabine (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Oxaliplatin (2) · liposomal doxorubicin (2) · Dexamethasone (1) · Diathermy (1) · Docetaxel (1) · Doxorubicin (1) · Enoxaparin (1) · Fluorouracil (1) · Folfox protocol (1) · Glucose (1)
Eli Lilly and Company (2) · AGO Study Group (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Boehringer Ingelheim (1) · Charite University, Berlin, Germany (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Ipsen (1) · Janssen Research & Development, LLC (1) · MEI Pharma, Inc. (1) · Merck Sharp & Dohme LLC (1) · Nanjing PLA General Hospital (1) · Novartis Pharmaceuticals (1) · Pierian Biosciences (1) · Sanofi (1)
United States (9) · France (8) · Australia (6) · Poland (6) · Belgium (5) · Germany (5) · Italy (5) · Spain (5) · Denmark (4) · Finland (4) · Russia (4) · United Kingdom (4) · Canada (3) · Czechia (3) · Greece (3)
Beate Rau, Prof. (1) · Cary Presant, MD (1) · Daniel P Gold, PhD (1) · Francois Quenet, MD (1) · Jacobus Pfisterer, MD PhD (1)
PMID 37407274, PMID 37185961, PMID 22987083, PMID 23109694, PMID 24318743, PMID 26003804, PMID 26590673, PMID 30630885, PMID 31371228, PMID 31924332, PMID 32717180, PMID 33476595, PMID 33891472, PMID 33960681, PMID 36123540, PMID 36332161, PMID 36595569, PMID 37625235, PMID 37906724, PMID 37922442, PMID 40374989, PMID 42705254
2005 (1), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2018 (1)